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Abstract
This study compared HIV-1 genotypes shed over time (≤3.5 years) in the vaginal secretions (VS) 
and blood plasma (BP) of 15 chronically infected women. Analysis of predicted coreceptor 
tropism (CCR5 = R5, CXCR4 = X4) for quasispecies shedding revealed three patterns: (1) viral 
quasispecies shed in both VS and BP were restricted to R5-tropism at all time points, (2) 
quasispecies shed in VS were restricted to R5-tropism at all time points but X4 quasispecies were 
identified in the BP at one or more time points, and (3) quasispecies shed in matched VS and BP 
both contained X4-tropic viruses. Overall, the frequency of X4 quasispecies circulation in VS was 
2-fold less than in BP and detection of X4 virus in VS was more likely to occur when X4 
quasispecies comprised more than 50% of BP viruses (p = 0.01) and when declines in blood CD4+ 
lymphocyte levels were the greatest (p = 0.038). Additionally, the mean number of predicted N-
glycosylation sites between matched VS and BP samples was strongly correlated (r = 0.86, p< 
0.0001) with glycosylation densities in the following order (VS R5 = BP R5 > BP X4 > VS X4). 
The X4 glycosylation densities may result from compartmentalization pressures in the female 
genital tract or the delayed appearance of these viruses in VS. Our results suggest that the presence 
of X4 virus in VS is associated with a threshold population of X4 quasispecies in BP, which are 
increasing during the HIV-induced failure of the human immune system.
Introduction
The genome of human immunodeficiency virus type 1 (HIV-1) can undergo extensive 
diversification during the natural course of infection.1–4 This diversification allows the virus 
to exist as a collection of closely related, but genetically distinct variants termed 
quasispecies, which can have different capacities to evade host immune responses, resist 
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antiretroviral drugs, and utilize different coreceptors for cell entry.5–12 Quasispecies in one 
tissue site can be distinct from those in another site, such as the previously described 
compartmentalization of HIV-1 in the female genital tract,13–16 and is not unexpected as 
local production of HIV-1 and anti-HIV-1 specific antibodies in the female genital tract has 
also been demonstrated.13,17–19 Although different patterns of evolution have been shown 
between HIV-1 in the genital secretions and blood of women in genetic analyses,15,20 data 
about how such differences might influence the phenotypes of viruses in these two tissue 
sites, especially during later disease stages, are limited.
In more than 95% of recently HIV-1-infected individuals, only non-syncytium-inducing 
(NSI) variants, which typically use the CCR5 (R5) protein to enter CD4+ cells, are 
detected.21 However, during disease progression approximately half of HIV-1 subtype B-
infected individuals show the emergence of syncytium-inducing (SI) viruses, which 
primarily utilize the CXCR4 (X4) transmembrane protein as a coreceptor for cell entry.21,22 
Data from both genotypic and phenotypic studies suggest that NSI/R5 variants are more 
readily transmitted than SI/X4 strains.23,24 A number of hypotheses have been offered to 
explain why SI/X4 viruses are not as readily transmitted via mucosal routes including that 
cotransmitted SI/X4 variants are more readily cleared by the host immune system,21 or that 
selective expression of the R5 cell-surface protein on target cells in the genital mucosa 
favors the transmission of R5-tropic NSI viruses.25 Little information has been reported 
regarding viruses in the sites relevant to most HIV-1 exposures worldwide, the genital tracts 
of infected men and women,26–29 where an increase in the relative abundance of NSI/R5-
tropic viruses could indeed facilitate selective transmission of these variants. A cross-
sectional genotyping study of a dozen women reported significant differences in the relative 
abundance of R5- and X4-tropic viruses between blood and vaginal secretions of some 
women, and X4-tropic viruses were detected only in the blood compartment for a majority 
of these women, although no longitudinal data were available.14
The emergence of SI/X4 viruses in BP has been linked to a rapid loss of CD4+ cells and a 
faster progression to AIDS.29 Studies have also shown that the appearance of SI/X4 viruses 
in peripheral blood has a transient nature. Specifically, data from a longitudinal study of nine 
males with slow or moderate disease progression indicated that SI/X4 viruses appeared in 
the blood during an intermediate disease stage and peaked just prior to transition into a late 
stage characterized by a decline of CD4+ cell counts to levels ≤200 cells/µl.30 Previous 
studies have not specifically addressed the longitudinal presence or absence of SI/X4 viruses 
in the female genital tract, or compared a woman’s immune status with the appearance of 
SI/X4 viruses within the vaginal compartment. Therefore, in this study we examined HIV-1 
envelope sequences of cell-free viruses in vaginal secretions and blood collected 
longitudinally from 15 HIV-1-infected women to compare predicted coreceptor phenotypes 
of viruses shed in these two anatomical sites over time.
Materials and Methods
Study population
This analysis includes data from examinations of women enrolled in the Emory Vaginal 
Ecology (EVE) Study of HIV-1 infection. HIV-1-infected women were eligible to enroll in 
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this study if they were 18–49 years of age, had a normal Pap smear within the previous 12 
months, were expected to live at least 1 year, and if on antiretroviral therapy (ART), had 
been using the same antiretroviral(s) for at least 3 months before enrollment. Exclusion 
criteria were as described elsewhere.31 Participants were requested to refrain from vaginal 
intercourse and the use of intravaginal medications for 72 h before their examinations.
This subpopulation of samples was chosen from the EVE study using the specific criterion 
that significant virus shedding was occurring in both blood and the genital tract at all three 
time points. This was done in order to detect and accurately analyze as many minor 
quasispecies in the genital tract as possible using our protocol. ART therapy at the time of 
the EVE study was still dual therapy in some early cases and only later was triple therapy in 
use. In addition, we have no data on ART adherence or ART failure due to resistance in the 
EVE study. Thus, the high level of virus shedding observed in this subpopulation of samples 
was likely due to women who were not on ART, suboptimal dual therapy ART, and possible 
nonadherence or failure of ART.
Specimens
Matched vaginal secretions (VS) and blood plasma (BP) were collected during clinical 
examinations at approximately ≥6-month intervals from 15 women enrolled in the EVE 
study. VS samples were obtained by introducing 10 ml of phosphate-buffered saline (PBS) 
into the vagina and collecting the pooled fluid in the posterior vaginal fornix. VS samples 
were tested for the presence of seminal fluid using an acid-phosphatase assay31,32 and blood 
contamination was estimated by a method previously described.31 Endocervical swabs were 
obtained to culture Neisseria gonorrhoeae and to test for Chlamydia trachomatis. Wet 
mounts were examined to detect Trichomonas vaginalis. Women subsequently diagnosed 
with genital tract infections were treated for those infections. Venous blood was collected at 
each examination in a CPT vacutainer tube that contained acid-citrate-dextrose 
anticoagulant. Samples were processed by previously described methods.31 All VS and BP 
samples used in this study had detectable virus loads determined by a quantitative assay for 
cell-free HIV-1 RNA described elsewhere.31,33
Cell-free HIV-1 RNA isolation, reverse transcription, and nested PCR
Cell-free HIV-1 was pelleted from 1-ml aliquots of cell-free VS and BP samples by 
centrifugation (105 × g) for 30 min. RNA was extracted from the pellets using the E.Z.N.A. 
Total RNA kit (Omega Bio-tek, Doraville, GA) and eluted in 50 µl of water according to the 
manufacturer’s protocol. RNA extractions of VS and BP samples were performed at separate 
times to prevent the possibility of cross-contamination of matched samples during this 
procedure.
One-tenth of the extracted RNA (5 µl) was reverse-transcribed for 30 min at 42°C using the 
GeneAmp RNA PCR kit (Perkin Elmer, Branchburg, NJ) and 50 pmol of an antisense 
primer (JH35R: 5′-CACTTCTCCAATTGTCCITCA-3′).34 The resulting complementary 
DNA was used in an nPCR protocol that amplifies a 540-bp fragment in the C2V4 region of 
the gp120 envelope gene (7002–7541 of HXB2).34 The broadly reactive primer sets (JH35R, 
JH44F: 5′-ACAGTRCARTGYA CACATGG-3′, JH33F: 5′-
Haaland et al. Page 3
AIDS Res Hum Retroviruses. Author manuscript; available in PMC 2017 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CTGTTIAATGGCAGICTAGC-3′, JH48R: 5′-RATGGGAGGRGYATACAT-3′) and nPCR 
cycling conditions were previously reported to amplify the C2V4 region from HIV-1 
subtypes B, C, D, and E.34 Reverse transcription and nPCR amplification of VS and BP 
samples were performed at separate times to prevent the possibility of cross-contamination 
of matched samples during this procedure.
Three independent RT-nPCRs were performed and pooled for each VS and BP sample in 
order to obtain a more accurate representation of the cell-free HIV-1 RNA quasispecies. In 
addition, amplifiable copies of C2V4 template RNA were estimated from the highest 
dilution of the RNA extract (100 to 103) that produced a 540-bp amplicon detectable by 
ethidium bromide staining of a 1% agarose gel in the RT-nPCR reactions described above. 
Negative control RT-nPCR reactions were performed with water as an input template.
Cloning and sequencing of HIV-1 env RT-nPCR products
For each VS and BP sample, the pooled HIV-1 env C2V4 RT-nPCR products were gel 
purified and then cloned using the TOPO TA kit (Invitrogen, Carlsbad, CA) according to the 
manufacturer′ s protocol. Plasmid DNA was isolated from 10 clones for each sample using 
the QIAprep Spin Miniprep kit (Qiagen, Valencia, CA), and HIV-1 env C2V4 inserts were 
sequenced using Visible Genetics′ OpenGene system. Sequence data were edited with the 
Sequencher 3.0 program (Gene Codes Corporation, Ann Arbor, MI), and an ~345-bp 
fragment that included a portion of the C2 region, and the entire V3 and C3 regions 
(C2V3C3) was analyzed. For each sequence, the predicted coreceptor tropism of the V3 
loop was determined using the PSSM program sinsi matrix (available at http://
indra.mullins.microbiol.washington.edu/webpssm/).35,36 The N-Glycosite tool (available at 
the Los Alamos HIV sequence database web site, http://hiv-web.lanl.gov) was used to 
identify potential N-linked glycosylation sites for each sequence. Phylogenetic trees were 
constructed using the MEGA 2.1 program (Tempe, AZ) by the neighbor-joining method 
using Kimura two-parameter distance matrices to ensure that no interpatient contamination 
was detected.
Statistical analyses
Statistical analyses were performed using the Instat 3.0 software package (GraphPad 
Software, Inc, San Diego, CA). A p value ≤ 0.05 was considered significant. Observed 
distributions were examined by chi square tests. Mann-Whitney and t tests were used to 
compare the number of N-glycosylation sites between VS and BP sequences. The 
proportions of predicted R5 viruses in VS and BP samples were compared in binomial 
proportions tests. Spearman rank correlation coefficients were calculated to assess 
relationships between clinical data (e.g., CD4+ cell levels and viral loads) and predicted 
coreceptor distributions and N-glycosylation densities for VS and BP samples. Mann-
Whitney tests and Kruskal-Wallis tests with Dunn’s multiple comparisons post tests were 
used to compare clinical data among patient groups defined by experimental findings (e.g., 
predicted R5 and X4 viruses, number of N-glycosylation sites).
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Nucleotide sequence accession numbers
The V3 nucleotide sequences reported in this study have been assigned GenBank accession 
numbers HQ822532–HQ 823431.
Results
Study participants
For this analysis we examined a total of 900 HIV-1 C2V3C3 env sequences from matched 
samples of VS and BP provided at 45 clinic visits of 15 HIV-1-infected women. For each 
woman, matched samples collected at three clinic visits were selected that spanned a total of 
1.5–3.5 years. Fifteen of 30 (50%) intervals between clinic visits were 1 year with 4, 7, 3, 
and 1 intervals at 0.5, 1.5, 2.0, and 2.5 years, respectively (rounded to nearest half year 
increment; all intervals ≥6 months, Table 1). A neighbor-joining phylogenetic tree 
constructed from all 900 HIV-1 env C2V3C3 sequences showed that sequences from the VS 
and BP samples of each patient clustered together without interpatient contamination (data 
not shown).
Each VS and BP sample had a measurable HIV-1 gag RNA virus load that was determined 
by a QC RT-PCR assay, as described previously.31 The median virus load for VS and BP 
samples was 6.0×104 total copies/VS (range, 1.1×103 to 1.4×107 total copies/VS) and 
8.7×104 copies/ml (range, 8.3×102 to 1.6×106 copies/ml, Table 1), respectively. The 
contribution of whole blood to vaginal virus load did not exceed 2% in any of the VS 
samples. At the first collection date, five, four, and four women had peripheral blood CD4+ 
cell counts >400 (high), 400–200 (medium), and <200 (low) cells/µl, respectively (Table 1). 
CD4+ cell count data were not obtained for two women on the first collection date, although 
both women had high CD4+ cell counts at the time of enrollment in the study. Yearly 
peripheral blood CD4+ changes ranged from +68 to −139 cells/µl/year (median=−62 cells/ 
µl/year), and by study end, one women had CD4+ cell counts in the high category, while six 
and seven women had CD4+ levels in the middle and low categories, respectively (the CD4+ 
cell count for the last collection time was not available for one woman). Four women were 
receiving antiretroviral therapy during all three clinic visits and another six women were 
receiving antiretroviral therapy at one or two clinic visits. Trichomonas vaginalis was 
detected at a single clinic visit of two women, and Chlamydia trachomatis was detected at 
one clinic visit of another woman (Table 1). Neither Neisseria gonorrhoeae nor seminal fluid 
was detected at any of the sampling times.
HIV-1 R5- and X4-tropic virus shedding in VS and BP
For each of the 10 clones sequenced from 45 matched VS and BP samples, HIV-1 
coreceptor tropism was predicted using the PSSM program. Each matched set of VS and BP 
samples was categorized as being composed of only R5-tropic viruses (23/45), X4-tropic 
viruses in plasma only (12/45), or X4-tropic viruses in the VS and BP (10/45). Less than 
one-half (10/22) of the matched samples where X4-tropic viruses were identified in BP had 
X4-tropic viruses in the matched VS sample. X4-tropic strains were not detected in VS at 
any collection time without also being detected in BP.
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Longitudinal analysis of the predicted coreceptor phenotypes shed in VS and BP of the 15 
women showed three distinct patterns over time. In one pattern, only predicted R5 viruses 
were shed in both VS and BP for all clinic visits of five women (Fig. 1A). In a second 
pattern, predicted X4 strains occurred only in BP of five women as a mixture with R5-using 
viruses at one or more sampling times (Fig. 1B). In the last pattern, predicted X4 viruses 
were found (alone or as a mixture with R5 strains) in both VS and BP samples of five 
women (Fig. 1C).
The above analysis of coreceptor detection at clinic visits suggested that the presence of X4-
topic virus in VS was associated with concurrent circulation in BP. Relative amounts of R5- 
and X4-tropic viruses were estimated from the sequences of the 10 clones from each VS and 
BP sample and are expressed by the proportion of R5 virus in a sample (λ = number of 
predicted R5-tropic clones/10 total clones; λ = 1 and 0 indicate all R5 and all X4-tropic 
viruses in a sample, respectively). Further analysis revealed a stochastic association between 
levels of X4 virus circulating in blood and detection in VS. Namely, X4 virus detection in 
VS was more likely to occur when X4 viruses comprised more than 50% of BP viruses 
(λ<0.5, p = 0.01) and even more so when they comprised more than 80% of BP viruses 
(λ<0.2, p = 0.002).
Immune status and HIV-1 coreceptor usage of viruses shed in VS and BP
Significant differences in yearly peripheral blood CD4+ decreases were found between 
women who shed exclusively R5 viruses and those that shed X4 viruses in BP only or in 
both VS and BP. For this analysis, yearly decreases in peripheral blood CD4+ cell levels 
(determined from all available data including data from clinic visits prior to or between the 
three collection times used in this study) were compared between women who shed 
exclusively R5 viruses in both VS and BP (Fig. 1A) and those who shed X4 at any collection 
time (Fig. 1B and C). Yearly peripheral blood CD4+ decreases were greater for women who 
shed predicted X4 viruses at any collection time (median loss=−2 and −79 CD4+ cells/µl/
year, for women with R5 only and X4 at any time, respectively, p = 0.038, Fig. 2). 
Differences between the starting blood CD4+ cell levels for these two groups were not 
statistically significant. This analysis of blood CD4+ cell level decreases excluded the two 
women noted above (patient ID 35 and 50) who shed predominantly X4 viruses in their VS 
and BP samples, but also had very low CD4+ cell levels (≤40 cells/µl) for all their clinic 
visits. Viral loads and antiretroviral therapy were not associated with the shedding of X4 
viruses in VS or BP samples.
A cross-sectional examination of our data using the relative amounts of R5 and X4 viruses in 
each sample indicated that greater amounts of X4-tropic viruses were associated with lower 
blood CD4+ cell levels for both VS and BP samples. Although modest, the rank correlations 
between blood CD4+ cell levels and λ values for VS and BP (r = 0.61, p<0.001; r = 0.45, p 
= 0.003, respectively) indicate that greater amounts of R5- and X4-tropic viruses are 
associated with higher and lower blood CD4+ cell levels, respectively, in both anatomical 
compartments.
Despite the correlation between the relative abundances of R5- and X4-tropic viruses in VS 
and BP (VS and BP λ values, r = 0.69, p<0.001) and the evidence that the abundances at 
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both sites appear to be influenced by a common factor (CD4+ cell level), significant 
differences between VS and BP λ values (≥ 0.4, p≤0.05) were found for seven (16%) 
matched sample pairs of four women (Table 1). No significant distinctions in blood CD4+ 
cell levels, viral loads, or use of antiretroviral therapy were found between these seven 
matched samples and the remaining VS and BP pairs.
N-Glycosylation densities of HIV-1 shed in VS and BP
Previous data suggest that N-linked carbohydrate moieties on the HIV-1 envelope may be 
important in virus infectivity and viral escape of host immune responses.37 To examine N-
glycosylation densities, we identified affected N-X-S/T sites in predicted amino acid 
sequences of VS and BP.38 The number of potential N-glycosylation sites ranged from 5 to 
10 sites (median=8) for VS sequences, and 5 to 9 sites for BP sequences (median = 8). Over 
time, changes in the mean number of N-glycosylation sites (calculated from the 10 
sequences from each sample) between consecutive sampling times ranged from 0 to 1.5 for 
VS samples (median = 0.3) and from 0 to 1.0 for BP (median=0.3). These changes were 
correlated between matched VS and BP samples (r=0.72, p<0.0001, data not shown), but 
they were not significantly associated with fluctuations in blood CD4+ cell levels or viral 
loads. Overall, the mean numbers of N-glycosylation sites between matched VS and BP 
samples were strongly correlated (r=0.86, p<0.0001). Even so, in comparisons of these mean 
N-glycosylation densities between paired samples, significant differences were found for six 
sampling times (13%) of five women (Table 1). No significant differences in blood CD4+ 
cell levels, viral loads, or the use of antiretroviral therapy were found between these six 
clinic visits and the remaining sampling times.
In cross-sectional examinations of N-glycosylation densities and CD4+ cell levels, a greater 
range of the number of VS and BP N-glycosylation sites was found for the low (<200 
cells/µl) and high ( >400 cells/µl) CD4+ cell level categories compared to the range observed 
for CD4+ cell counts of 200– 400 cells/µl. Also, N-glycosylation densities among the three 
CD4+ cell level categories showed significant differences in both VS and BP, with the 200–
400 cells/µl category having a higher number of N-glycosylation sites than the low or high 
CD4+ cell level categories (Fig. 3A).
A previous study of N-glycosylation sites in R5- and X4-tropic viruses reported strain-
specific differences.39 In our study, a cross-sectional examination of all sequences showed 
that R5 viruses had higher N-glycosylation densities than X4 viruses (medians = 8.0 and 7.0, 
respectively, p < 0.0001). Further analysis revealed VS X4 sequences had significantly fewer 
sites than BP X4 viruses to yield the following order of N-glycosylation densities: BP R5 ~ 
VS R5 > BP X4 > VS X4 viruses (Fig. 3B). However, when these analyses were performed 
individually for each of the five patients who had predicted X4 viruses in both her VS and 
BP samples, this trend in N-glycosylation densities was significant only for patient 035.
Discussion
Many studies of HIV-1 transmission report detection of R5-tropic viruses only in individuals 
newly infected through heterosexual contact.21,23,24 Our study sought to determine if this 
predominance of R5-tropic sexual transmission could be due in part to a relative scarcity of 
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X4-tropic virus shedding in genital secretions compared to that in the blood of chronically 
infected women. We also wanted to know if differences in predicted glycosylation densities 
between VS and BP reported in cross-sectional studies14 were maintained over time. Finally, 
we sought to know if predicted viral tropism and glycosylation patterns in HIV from VS and 
BP were affected differently by changes in the immune status of chronically infected 
women.
Our analysis of the predicted amino acid sequences of genomic viral RNA indicates that R5-
tropic viruses were the most common variant in VS samples but that X4 strains were also 
present at 10 (22%) study visits and comprised all the VS quasispecies sampled at five 
(11%) of those visits. Although X4 viruses were present in blood without being detected in 
matched VS samples, they were detected in VS only when X4 viruses were present in BP. 
This suggests that shedding of X4 viruses in female VS is preceded by that in peripheral 
blood. In fact, our detection of X4 shedding in VS was more likely to occur when X4 viruses 
were 50% or more of the blood quasispecies in a matched BP sample. In addition, our 
results and a previous study14 showed that when there was a significant difference in the 
ratio of R5/X4 viruses between matched VS and BP samples, the proportion of X4 viruses 
was always higher in BP. However, it is likely that neither the X4 nor R5 viruses circulating 
in peripheral blood become a significant proportion of the cell-free HIV-1 that is shed in a 
woman’s genital secretions. We have previously reported that local virus replication in the 
female genital tract, not transudation of cell-free virus from blood plasma, is the major 
source of HIV in women’s genital secretions.19 In addition, we determined that less than 5% 
of a vaginal virus load during intermenses is due to whole blood mixing with vaginal 
secretions.40–42
As HIV-1 disease evolves, coreceptor switching from R5 to X4 tropism in blood is common 
among subtype B HIV-1-infected individuals.12 The R5-to-X4 coreceptor switch is often a 
precursor of accelerated clinical disease progression accompanied by a large decline in 
peripheral blood CD4+ cell counts.12,29,30,43 In our study, there was an overall correlation 
between VS and BP R5/X4 virus ratios and CD4+ cell counts. In addition, our longitudinal 
analysis showed that women who had greater declines in CD4+ cell counts over time were 
more likely to shed X4 viruses in VS as well as BP. These results suggest that the immune 
dysregulation during HIV-1 disease progression that allows for increased shedding of X4-
tropic viruses in the female genital tract is similar to that in blood.
The mechanism for coreceptor switching to X4 virus shedding in women’s genital secretions 
is not known. Reports that indicate local virus replication as the major source for most of the 
HIV shed in the female genital secretions19,40,42 predict that infected cells replicating X4 
virus in the mucosa are necessary for X4 shedding in the female genital tract. Thus, these 
X4-infected cells could arrive from peripheral blood as part of the transient population of 
CD4+ lymphocytes with mucosal homing receptors that infiltrate the genital mucosa on a 
continual basis.44,45 This concept is further supported by observations that virus-infected 
cells trafficking from peripheral blood is the major proviral pool of infected cells in the 
genital mucosa and that mucosal proviral evolution is not compartmentalized from that in 
blood over time.15 In contrast, previous cross-sectional studies report molecular evidence of 
limited HIV RNA compartmentalization in women’s genital tissues14 that could possibly 
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support an independent evolution of X4 viruses. However, the evidence that X4-tropism 
evolves in the thymus and not other tissues such as lung, lymph nodes, and spleen46 suggests 
that the female genital tract would also likely not support an independent evolution of X4-
tropism.
In addition to similar coreceptor tropism profiles between VS and BP, we also found a strong 
correlation for N-glycosylation densities between matched VS and BP samples. Moreover, 
changes in N-glycosylation densities over time were correlated between matched VS and BP 
samples. These results suggest that N-linked carbohydrate density in PB and VS is usually 
affected by one or more common factors. Our data indicated that immunological integrity 
could be a factor; both VS and BP viruses had lower N-glycosylation densities at lower 
blood CD4+ cell levels (<200 cells/µl) compared to more moderate levels (400–200 cells/µl) 
as reported in a previous cross-sectional study.14 Since N-linked carbohydrates on the viral 
envelope are implicated in the resistance to antibody-mediated neutralization,14,47,48 the 
decline of host immunity (CD4+ cell counts <200 µl) may have decreased the selective 
pressure for maintaining these glycosylation sites as discussed previously.39,47 Yet we were 
surprised that viral glycosylation density was also lower at high CD4+ cell levels (>400 
cells/µl) compared to those at moderate levels (400–200 cells/µl). However, data from 
Bunnik et al.49 showed that predicted env glycosylation densities in proviral DNA from 
peripheral blood mono-nuclear cells of infected persons continued to increase for as long as 
3.5 to 8 years after seroconversion in chronically infected persons and peaked after their 
CD4+ levels were <400 cell/µl. Thus, our data expand on this previous study to show that 
glycosylation densities of HIV shed in both VS and BP of chronically infected women 
continue to increase during the early and middle phases of HIV-induced immune 
suppression.
Despite the evidence that N-glycosylation densities of HIV-1 in both VS and BP are 
associated with immune status, significant differences in the carbohydrate densities of 
matched VS and BP samples did occur in a small percentage of clinic visits for 33% of the 
women in our study. At some of those visits, VS and BP glycosylation differences could be 
explained by corresponding differences in their predicted coreceptor tropism. At the 
remaining visits where glycosylation densities were different but coreceptor tropism was 
similar, there was no trend for glycosylation being higher in VS or BP. In addition, 
differences in VS and BP glycosylation densities were transient; none of the women 
sustained a significant glycosylation difference for all three clinic visits and only one woman 
did for two visits. Thus, the lack of persistent glycosylation differences we observed 
between HIV shed in VS and BP suggests that mucosal immune pressures against virus in 
the women′s genital mucosa were not driving HIV glycosylation densities independent of 
that in peripheral blood over time. However, our finding of lower glycosylation densities for 
X4 viruses in VS compared to BP may indicate that X4 virus shedding in the female genital 
tract undergoes selection for fewer N-glycosylation sites. However, the fact that most X4 
virus in VS was detected later in disease progression when overall glycosylation densities 
were lower suggests that the level of overall immune dysfunction and not a 
compartmentalized mucosal selection mechanism was the dominant factor of this difference.
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In summary, our longitudinal study of predicted HIV-1 coreceptor usage and envelope 
glycosylation density supports the concept of a dynamic process whereby subpopulations of 
infected cells in peripheral blood continually migrate to mucosal tissues, clonally expand, 
and shed virus in a woman’s genital secretions.50 Although our longitudinal study was not 
designed to use currently accepted genotype compartmentalization analyzes for VS and BP 
viruses,51,52 our results support other longitudinal studies that showed a lack of sustained 
compartmentalized evolution of HIV-1 in the genital mucosa of women.53 In fact, our results 
and those in a previous study that reported a pattern of similar anti-retroviral therapy-
associated resistance mutations between viruses in VS and PB over time54 provide further 
evidence that mucosal tissues are continually being repopulated with HIV-infected cells 
migrating from peripheral circulation. As the samples selected for this study contained high 
virus loads in both VS and BP, future longitudinal studies will also need to examine the 
coreceptor tropism of virus in women with low virus loads. The presence of significant 
levels of X4 tropic virus in VS during mostly late-stage disease suggests that these genital 
tract viruses are available for sexual transmission. However, it is unknown whether these 
genital tract viruses are less transmissible or that decreased sexual activity due to high-level 
morbidity during late stage disease is responsible for their lack of transmission. Moreover, as 
R5-tropic entry inhibitors such as Maraviroc come into wider use therapeutically and 
possibly as a microbicide agent, it will be important to determine if they significantly 
increase X4 virus genital shedding in persons failing therapy and if those X4 viruses are 
more infectious and more pathogenic following sexual transmission.
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FIG. 1. 
Schematic showing the relative abundance of predicted R5 and X4 viruses being shed in 
vaginal secretions (VS) and blood plasma (BP) samples over time for each woman. The top 
and bottom halves of each bar (separated by a dashed white line) represent VS and BP 
viruses, respectively, and solid and patterned bars indicate predicted R5 and X4 coreceptor 
usage, respectively. Women are grouped as those who had (A) only predicted R5 viruses 
being shed in VS and BP for all sampling times; (B) predicted X4 viruses shed in BP for ≥ 1 
sampling time(s); and (C) predicted X4 viruses being shed in both their VS and BP for ≥1 
sampling time(s).
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FIG. 2. 
Comparison of changes in CD4+ cell levels for women who shed predicted R5 viruses only, 
or X4 viruses in VS and/or BP samples for ≥1 sampling times. Horizontal lines indicate 
median change in CD4+ cell level/year for each group. Two women (patient IDs 35 and 50 
with CD4+ cell level changes shown as unfilled circles) were excluded from this analysis 
because their CD4+ cell levels were very low for all sampling dates (≤40 cells/µl).
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FIG. 3. 
Cross-sectional analyses of the potential N-glycosylation densities of HIV-1 C2V3C3 
sequences. (A) A comparison of the number of N-glycosylation sites for VS (unfilled boxes) 
and BP (shaded boxes) sequences grouped according to CD4+ cell counts. (B) Comparison 
of the number of N-glycosylation sites between sequences grouped according to predicted 
coreceptor usage and sampling site. In these plots, the N-glycosylation densities within the 
25– 75% statistical quartiles are represented by boxes and solid lines through boxes are the 
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medians. N-Glycosylation densities within the 10–90% statistical intervals are represented 
by error bars and outlier data are shown as filled circles.
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